ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,806,756 | +4.9% | 361,029 | 0.0% | 0.02% | +29.4% |
| Q2 2023 | $32,221,838 | -17.8% | 361,029 | -1.2% | 0.02% | -22.7% |
| Q1 2023 | $39,187,623 | -12.4% | 365,488 | -0.2% | 0.02% | -15.4% |
| Q4 2022 | $44,716,434 | +18.3% | 366,138 | 0.0% | 0.03% | +13.0% |
| Q3 2022 | $37,808,000 | +11.1% | 366,138 | 0.0% | 0.02% | +21.1% |
| Q2 2022 | $34,037,000 | -20.8% | 366,138 | 0.0% | 0.02% | -5.0% |
| Q1 2022 | $42,970,000 | -14.1% | 366,138 | -1.5% | 0.02% | -9.1% |
| Q4 2021 | $50,008,000 | -16.8% | 371,729 | -1.4% | 0.02% | -24.1% |
| Q3 2021 | $60,102,000 | +85.1% | 377,075 | +52.7% | 0.03% | +81.2% |
| Q2 2021 | $32,474,000 | +3.6% | 246,859 | +1.5% | 0.02% | -5.9% |
| Q1 2021 | $31,352,000 | -28.1% | 243,261 | -7.0% | 0.02% | -37.0% |
| Q4 2020 | $43,627,000 | +8.0% | 261,578 | -0.1% | 0.03% | -3.6% |
| Q3 2020 | $40,396,000 | +10.7% | 261,766 | +6.1% | 0.03% | 0.0% |
| Q2 2020 | $36,498,000 | +25.4% | 246,780 | -4.5% | 0.03% | +7.7% |
| Q1 2020 | $29,106,000 | -23.6% | 258,467 | -5.7% | 0.03% | +4.0% |
| Q4 2019 | $38,118,000 | +54.7% | 274,000 | +7.1% | 0.02% | +47.1% |
| Q3 2019 | $24,633,000 | -44.4% | 255,759 | -33.6% | 0.02% | -34.6% |
| Q2 2019 | $44,335,000 | +35.1% | 385,044 | +38.1% | 0.03% | +30.0% |
| Q1 2019 | $32,817,000 | +335.5% | 278,830 | +131.8% | 0.02% | +300.0% |
| Q4 2018 | $7,535,000 | -45.4% | 120,287 | -38.2% | 0.01% | +25.0% |
| Q3 2018 | $13,794,000 | +0.0% | 194,687 | -6.1% | 0.00% | 0.0% |
| Q2 2018 | $13,788,000 | +106.5% | 207,301 | +103.0% | 0.00% | +33.3% |
| Q1 2018 | $6,677,000 | +122.0% | 102,117 | +36.0% | 0.00% | +50.0% |
| Q4 2017 | $3,008,000 | -10.4% | 75,093 | -19.0% | 0.00% | 0.0% |
| Q3 2017 | $3,358,000 | +229.9% | 92,680 | +152.6% | 0.00% | +100.0% |
| Q2 2017 | $1,018,000 | +50800.0% | 36,692 | +36592.0% | 0.00% | – |
| Q1 2017 | $2,000 | +100.0% | 100 | +26.6% | 0.00% | – |
| Q1 2016 | $1,000 | -98.7% | 79 | -98.2% | 0.00% | – |
| Q4 2015 | $79,000 | – | 4,318 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |